Breast disease

QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis

Retrieved on: 
Tuesday, April 16, 2024
Research, Medical Devices, Women, Clinical Trials, Biotechnology, Radiology, Consumer, Health, Science, Oncology, FDA, University, ROC, Cancer, Woman, Breast cancer, Breast disease, Tomosynthesis, MD, 3D, DBT, QTI, Patient, MRMC, AUC, Recall, Medical imaging

The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.

Key Points: 
  • The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.
  • This means that QTI technology is non-inferior to DBT in the detection of breast lesions as a whole, with high specificity in determining benign cysts and thus decreasing benign recall rates.
  • Unfortunately, routine screening mammograms are not recommended for women under 40 because risks outweigh potential benefits at this young age.
  • Fortunately, the now published results suggest that QTI’s technology can be a much-needed potential alternative to mammography for women too young to undergo mammography screening.

Asia Breast Cancer Screening Market Size and Forecast Report 2023-2028: Industry Trends, Growth, Share, Outlook, Opportunities, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, January 19, 2024
Oncology, Health, Consumer, Women, Health Technology, Other Health, Ageing, Obesity, Woman, Mammography, Patient, Breast, Infection, Research, MRI, TSCO, KCSG, Breast cancer, Government, Life expectancy, Investment, BIG, Urbanization, CMEA, Tobacco, Non-governmental organization, Breast disease, Diagnosis, Breast International Group, Medical imaging

The "Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • With its rapid population growth trajectory, India is poised to make significant strides in the Asia Breast Cancer Mammography Screening industry
    By Mammography Screening, Asia Breast Cancer Screening Market is segmented into China, India, Japan, Korea, Singapore, Thailand and Malaysia.
  • By MRI Screening, Asia Breast Cancer Screening Market is divided into China, Japan, India, Korea, Singapore, Thailand and Malaysia.
  • With its accelerating growth rate, China is poised to dominate the Asia Breast Cancer Ultrasound Screening industry
    By Ultrasound Screening, Asia Breast Cancer Screening Market is classified into China, Japan, Korea, Singapore, India, Thailand and Malaysia.

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Retrieved on: 
Monday, October 30, 2023
DCIS, FDA, NCI, Atossa, Testosterone, Biomarker, SERM, MD, Breast disease, Growth, Ductal carcinoma, Disease, Risk, Tamoxifen, National Cancer Institute, Breast cancer, SAN, Woman, Safety, Anastrozole, Patient, Toxicity, Breast, Pharmaceutical industry, Birth control

SAN FRANCISCO, Oct. 30, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, a selective estrogen receptor modulator (SERM) in development by Atossa Therapeutics (Nasdaq: ATOS); HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways in development by Havah Therapeutics; and ORSERDU® (elacestrant), the only FDA approved oral selective estrogen receptor degrader (oSERD) in development by Stemline Therapeutics Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group. 

Key Points: 
  • Surgery is the current standard treatment for DCIS even though many patients never progress to breast cancer, which means that patients are often over-treated with invasive procedures.
  • A key element in reducing overtreatment of DCIS is identifying biomarkers that reflect the risk of progression so that those with low-risk lesions are spared surgery.
  • RECAST DCIS features the assessment of imaging and molecular-based biomarkers in addition to evaluating new investigational agents in this setting.
  • The three collaborators for this trial, Atossa Therapeutics, Havah Therapeutics, and Stemline, all aim to find alternative solutions for DCIS patients and are providing different agents for assessment.

TransMed7, LLC Announces First Revenue from Concorde Family of Devices

Retrieved on: 
Wednesday, September 6, 2023
Medical Devices, Surgery, Women, Health Technology, Biotechnology, Radiology, General Health, Consumer, Health, Oncology, Single, Surgeon, Bleeding, Teaching, Marie Cassidy, Speedbird, Breast disease, Sale, Bruise, Stereotactic surgery, Patient, Physician, Architecture, Growth, Society, Medical imaging, Concorde

“After performing a series of breast biopsies using SpeedBird and Concorde devices, I examined all these patients in a standard follow up consultation.

Key Points: 
  • “After performing a series of breast biopsies using SpeedBird and Concorde devices, I examined all these patients in a standard follow up consultation.
  • Concorde devices include an outer scoopula-shaped shield that adds an additional directionality capability and an easily recognizable reference structure for exceptional ultrasound and stereotactic/tomosynthesis accuracy.
  • SpeedBird and Concorde devices have a proprietary flashing image which makes it nearly impossible to lose sight of the biopsy needle.
  • We anticipate strong growth in the adoption of our SpeedBird and Concorde devices by surgeons and radiologists.

Learn-Look-Locate Strengthens Growing Panel of Advisors With Influential Trailblazers in Cancer Research, Genetic Testing, Artificial Intelligence, and Restorative Tattooing: Dr. Maryam Lustberg, Lauren Giannetti Sferrazza, Stacey Stevens, and Marnie Rust

Retrieved on: 
Thursday, May 18, 2023
Survivor, Partnership, Education, Friends, Myriad Genetics, Genetic counseling, Heredity, Breast, AAM, Cancer, Yale Cancer Center, Risk assessment, Woman, Wall Street, Associate, LLL, Yale School of Medicine, Genetics, Estate (law), Patient, Breast cancer, Breast disease, Chief Medical Advisor to the President, Internal medicine, Yale University, Diagnosis, CPCP, MPH, Mammography, News, Thyroid cancer, Disease, Medical imaging, MD

Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.

Key Points: 
  • Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.
  • Dr. Lustberg is an acclaimed physician and researcher with an extensive background in all-phase clinical trials and breast cancer translational research.
  • Lauren Giannetti Sferrazza, MS CGC, is a certified genetic counselor who currently practices as a National Medical Science Liaison in Oncology at Myriad Genetics.
  • And in addition, LLL and Dr. Charles Weaver already release a monthly Breast Cancer Newsletter that offers support from diagnosis through treatment, and into survivorship.

NeoDynamics, Inc. Announces U.S. Availability of NEONAVIA, the First and Only Pulse Biopsy Technology, FDA-Cleared in Breast and Axillary Lymph Node Biopsies

Retrieved on: 
Thursday, April 27, 2023
Gaylord National Resort & Convention Center, Pathology, Breast disease, Needle, PULSE, American Society of Breast Surgeons, Patient, Annual general meeting, Diagnosis, Commercial, SBI, Society, Convention center, Medtech, Breast cancer, Medical imaging

MATAWAN, N.J., April 27, 2023 /PRNewswire/ -- NeoDynamics, Inc., a MedTech company pioneering innovative technologies to advance the diagnosis and care of breast cancer today announced the U.S. availability of NEONAVIA, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.

Key Points: 
  • - Commercial launch and introduction of NEONAVIA scheduled at 2 upcoming Conferences for Breast Surgeons and Breast Imaging Professionals.
  • - NEONAVIA PULSE Study abstract has been accepted for electronic presentation at the 2023 SBI Breast Imaging Symposium.
  • "We look forward to meeting with the thought leaders and multi-stakeholders at these important venues advancing breast care through early detection, diagnosis, and treatment.
  • NEONAVIA's PULSE study, has been accepted for electronic presentation at the 2023 SBI Breast Imaging Symposium.

TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch

Retrieved on: 
Monday, February 6, 2023
Surgery, Health, Medical Devices, Breast disease, SBI, Physician, Diagnosis, Patient, Biopsy, Concorde, American Society of Breast Surgeons, Speedbird, FDA, Architecture, Stereotactic surgery, Multimedia, Society, Medical imaging

These cases demonstrated Concorde’s combined forward and side coring action, which is unique to the Concorde family of advanced breast biopsy devices, and is designed to add a vital layer of precision, control, efficiency and confidence for biopsy procedure under advanced imaging modalities.

Key Points: 
  • These cases demonstrated Concorde’s combined forward and side coring action, which is unique to the Concorde family of advanced breast biopsy devices, and is designed to add a vital layer of precision, control, efficiency and confidence for biopsy procedure under advanced imaging modalities.
  • View the full release here: https://www.businesswire.com/news/home/20230206005223/en/
    Concorde US biopsy device shown with detachable VacuPac® for completely tetherless operation (Photo: Business Wire)
    Dr. Berry commented, “I was delighted to perform the first clinical cases using TransMed7’s new Concorde US ultrasound-guided soft tissue breast biopsy devices.
  • I finished these biopsy procedures in an average of less than 5 minutes, which represents significant cost savings as well.
  • The Concorde ST device is designed for stereotactic and 2D/3D tomosynthesis guidance breast biopsy procedures with full, built-in (console-replacing) capabilities.

Dr. David Weintritt Brings Innovative Treatment to Breast Cancer Patients in Northern Virginia

Retrieved on: 
Monday, October 3, 2022
Air force, Physician, Perfusion, Health, DC, Multimedia, University of Virginia Cancer Center, View, Breast disease, Andrews Air Force Base, Walter Reed Army Medical Center, University, Lymph, Quality of life, Breast cancer, Patient, United, Private practice, FACS, Woman, Birth control, Medicine, Medical imaging, MD

FAIRFAX, Va., Oct. 3, 2022 /PRNewswire/ -- Virginia Cancer Specialists is proud to announce that David Weintritt, MD, FACS, one of the nation's most innovative breast surgeons, is joining their community-based cancer treatment team.

Key Points: 
  • FAIRFAX, Va., Oct. 3, 2022 /PRNewswire/ -- Virginia Cancer Specialists is proud to announce that David Weintritt, MD, FACS, one of the nation's most innovative breast surgeons, is joining their community-based cancer treatment team.
  • Weintritt says Virginia Cancer Specialists offers him the opportunity to practice in a holistic environment where all the needs of patients can be met through the resources Virginia Cancer Specialists has to offer.
  • "With his focus on promising new surgical advancements in breast cancer treatment, Dr. Weintritt is a welcome addition to our breast cancer team as we seek to deliver the very best in integrated care to our breast patients."
  • In 2003, Dr. Weintritt moved his practice to Alexandria, VA, bringing new programs and breast surgery techniques to Northern Virginia.

TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch

Retrieved on: 
Tuesday, August 9, 2022
Medical Devices, Surgery, Women, Health Technology, Other Health, Radiology, General Health, Consumer, Health, Oncology, Speedbird, FDA, SISS, Cardiovascular disease, Radiological Society of North America, Single, RSNA, CEO, Technology, Needle, Regenerative medicine, SBI, LLC, Society, Breast biopsy, Atlantic Film Festival, Breast disease, Patient, Learning curve, Architecture, Concorde, Physician, Solution, Biopsy, Medicine, Adoption, American Society of Breast Surgeons, Medical imaging, Medical device, Sparrow

Zero5 forward coring technology enables these devices to reliably and consistently obtain full-core, uniform-diameter samples with intact architecture from all of the various soft tissues.

Key Points: 
  • Zero5 forward coring technology enables these devices to reliably and consistently obtain full-core, uniform-diameter samples with intact architecture from all of the various soft tissues.
  • We are delighted to announce the successful clinical utilization of our production level, minimally invasive breast biopsy devices as we formally roll out our commercial launch, stated Dr. Vetter.
  • The Concorde ST device is designed for stereotactic and 2D/3D tomosynthesis guidance breast biopsy procedures with full, built-in (console-replacing) capabilities.
  • Look for announcements of first clinical case results of the Concorde family of Breast Biopsy devices in the coming weeks.

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022
Social conditions in Honduras, Headquarters, China Media Group Headquarters, CEO, Universities of Lille, Leadership, Research, Environment, Pfizer, Compliance, Suzhou Industrial Park, BMS, Patient, Discovery, Process, Early, HKEX, Therapy, Safety, Drug development, Novartis, Nature, Breast disease, News, AstraZeneca, MD, Medicine, ICB, Bristol Myers Squibb, Pharmaceutical industry, Medical device, Ribociclib, Neratinib

Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.

Key Points: 
  • Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.
  • During her time at AstraZeneca, Dr. Germa built an Early Development Clinical Group with over 180 staff and guided the clinical development of the early oncology portfolio.
  • "I would like to express my warmest welcome to Dr. Germa on her appointment," said Dr. Xueming Qian, CEO of Transcenta.
  • I am thrilled to join Transcenta at this important juncture," said Dr. Caroline Germa, Executive Vice President, Global Medicine Development and Chief Medical Officer of Transcenta.